IL6 and melanoma: Recently, Weber et al. [12] have reported that high baseline serum interleukin-6 (IL-6) levels are associated with a shortened survival in melanoma patients receiving nivolumab alone or ipilimumab alone, within the CheckMate 064 trial population [13].